Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Name

Click to order products ascending

Display 30 Products per page

bardoxolone methyl
Read More
Bardoxolone methyl (AbbVie/Kyowa Hakko Kirin), under development by the research-stage company Reata Pharmaceuticals, is a Phase III candidate in clinical trials for the treatment of pulmonary arterial hypertension.
October 29, 2018
Find out more
baricitinib
Read More
Baricitinib is an oral reversible inhibitor of Janus kinase-1 (JAK1) and JAK2 – that is JAK3-sparing – under co-development by Incyte and Eli Lilly. It is currently in development for the treatment of inflammatory conditions including…
October 4, 2016
Find out more
Bavencio
Read More
Bavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein.
March 6, 2019
Find out more
Bax 817
Read More
BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…
March 14, 2016
Find out more
Bay 94-9027
Read More
BAY 94-9027 (Bayer) is a long-acting recombinant factor VIII (rfVIII) product under development for the treatment of hemophilia A.
May 4, 2018
Find out more
bb2121
Read More
Pipeline product bb2121 (Celgene/bluebird bio) is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a promising target for immunotherapy which is found in 60–70% of multiple myeloma (MM) patients.
August 9, 2018
Find out more
Bempedoic Acid Franchise
Read More
Bempedoic acid is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis.
November 20, 2019
Find out more
BeneFix
Read More
BeneFIX (Pfizer) is an recombinant factor IX (rfIX) therapy indicated for the control and prevention of bleeding in hemophilia B.
May 4, 2018
Find out more
Beraprost 314d
Read More
Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…
June 19, 2015
Find out more
Betalutin
Read More
Betalutin is a first-in-class antibody-radionucleotide conjugate targeted to CD37, an alternative to CD20, which is widely targeted in non-Hodgkin’s lymphoma. CD37 is highly expressed in B cells and B-cell lymphomas.
January 31, 2019
Find out more
Betaseron
Read More
Betaseron was the first drug to reach the market that modifies the course of multiple sclerosis (MS), after launching in the US in 1994 and the EU in 1996 (where it is marketed as Betaferon).
November 24, 2017
Find out more
Betrixaban
Read More
Betrixaban (Portola Pharmaceuticals) is an oral, once-daily inhibitor of factor Xa that catalyzes conversion of prothrombin to thrombin, preventing thrombosis. Betrixaban is currently in Phase III development…
August 2, 2016
Find out more
Bevespi Aerosphere
Read More
Bevespi Aerosphere ([formoterol + glycopyrrolate]; AstraZeneca) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist (LABA) formoterol and the long-acting muscarinic antagonist (LAMA) glycopyrrolate, delivered via a pressurized metered dose inhaler.
July 31, 2018
Find out more
Bevyxxa
Read More
Bevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness.
January 23, 2018
Find out more
Bexsero
Read More
Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in adolescents and young adults from 10 years through to 25 years of age in the US, and in individuals two months of age and older in the EU. Bexsero contains three surface-exposed recombinant proteins: factor H binding protein, Neisseria adhesin A, and Neisseria heparin-binding antigen. It also includes New Zealand strain outer membrane vesicles. The antibodies generated after immunization with Bexsero target the aforementioned surface proteins present on the outer membrane vesicles.
September 3, 2019
Find out more
Biktarvy
Read More
Biktarvy ([bictegravir + emtricitabine + tenofovir alafenamide (TAF)]; Gilead) is an single-tablet regimen (STR) approved for the treatment of HIV-1 infection. It is a co-formulation of Gilead’s novel integrase strand transfer inhibitor (INSTI) bictegravir, and the marketed drug Descovy, which is a fixed-dose combination (FDC) of the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine and TAF.
June 28, 2019
Find out more
Binimetinibi
Read More
Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK pathway.
May 23, 2018
Find out more
Blincyto
Read More
Blincyto, produced in Chinese hamster ovary cells, is a bispecific T-cell engager that directs T-cells to target CD19-positive benign and malignant B-cells. It activates endogenous T-cells by connecting…
October 9, 2018
Find out more
blisibimod
Read More
Blisibimod is a selective antagonist of B-cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) that is in Phase III development for SLE. Elevated levels of BAFF have also been associated with several B-cell-mediated autoimmune diseases including…
April 5, 2016
Find out more
Bococizumab
Read More
Bococizumab is an antidyslipidemic humanized antibody that inhibits PCSK9. PCSK9 is a protease involved in the intracellular and extracellular regulation of LDL receptor (LDLR) expression…
June 29, 2016
Find out more
Bosulif
Read More
Bosulif is a kinase inhibitor that targets the BCR-ABL kinase and also inhibits the Src-family kinases that include Src, Lyn, and Hck. The BCR-ABL kinase is upregulated in the presence of an abnormal BCR-ABL fusion protein…
December 7, 2017
Find out more
Breo Ellipta
Read More
Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
July 31, 2018
Find out more
Brilinta
Read More
Brilinta (ticagrelor; AstraZeneca/The Medicines Company) is an antiplatelet agent designed to inhibit blood clot formation. It works by reversibly binding to the blood platelets’ adenosine diphosphate (ADP) P2Y12 receptor…
April 14, 2016
Find out more
Brintellix
Read More
Brintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder. The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram).
May 5, 2016
Find out more
Briviacti
Read More
Briviact (brivaracetam; UCB) is a follow-on product to Keppra (levetiracetam; UCB/Otsuka), acting as an anticonvulsant by binding to the synaptic vesicle glycoprotein 2A (SV2A), directly causing…
June 7, 2016
Find out more
Bronchitol
Read More
Bronchitol is an inhaled dry powder formulation of mannitol, a naturally occurring monosaccharide that also acts as a mucolytic agent.
September 3, 2018
Find out more
Buparlisibi
Read More
Buparlisib is a pan-PI3K inhibitor that attempts to counteract the dysregulation of the PI3K/protein kinase B (AKT) pathway in cancerous tissues…
May 2, 2016
Find out more
Bydureon
Read More
Bydureon (exenatide long-acting release; AstraZeneca) is a member of the glucagon-like peptide-1 (GLP-1) agonist class.
November 7, 2017
Find out more
Byetta
Read More
Byetta (exenatide; AstraZeneca) is a member of the glucagon-like peptide-1 (GLP-1) agonist class.
November 7, 2017
Find out more
C-Cure
Read More
C-Cure is a bone marrow-derived stem cell therapy aimed at regenerating cardiac tissue following severe damage due to myocardial infarctions.
December 11, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *